The relationship between sarcopenia detected in newly diagnosed colorectal cancer patients and FGF21, irisin and CRP levels.
Bio-electric impedance analysis
Colorectal cancer
FGF21
Irisin
Sarcopenia
Journal
European geriatric medicine
ISSN: 1878-7649
Titre abrégé: Eur Geriatr Med
Pays: Switzerland
ID NLM: 101533694
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
30
12
2021
accepted:
24
02
2022
pubmed:
13
3
2022
medline:
18
8
2022
entrez:
12
3
2022
Statut:
ppublish
Résumé
Sarcopenia is a progressive and generalized syndrome that can be linked to many causes such as cancers, and is caused by a quantitative and qualitative disorder (loss of muscle strength and/or physical performance) of skeletal muscle mass. Although sarcopenia has some hypothetical explanation in clinical practice, the mechanisms underlying this condition have not been clearly differentiated in patients with cancer. We aimed to investigate the relationship between irisin, FGF21 and CRP in detecting sarcopenia in colorectal cancer patients. Current prospectively study included non-metastatic newly diagnosed colorectal cancer patients. Patients were divided into 2 groups of 25 people, those with and without sarcopenia. Body composition measurements by examined by BIA. To measure the level of iris and FGF21 from patients, blood samples were taken into the biochemistry tube and their levels were measured. The median age of the patients included in the study was 60 years (range: 21-81), 68% were men. It was found that there was a significant relationship between sarcopenia and gender and BMI measurement. When Spearman correlation analysis was performed between skeletal muscle mass index and FGF21, irisin and CRP, there was a positive correlation between skeletal muscle mass index and irisin and FGF21, while there was a negative correlation between skeletal muscle mass index and CRP. [respectively: (r: 0.282, p: 0.048), (r: 0.564, p: < 0.001) and (r: - 0.360, p: 0.010)]. Similar results were found between hand-grip strength and FGF21, irisin and CRP. [respectively: (r: 0.342, p: 0.015), (r: 0.290, p: 0.041) and (r: - 0.476, p < 0.001)]. When sarcopenia was treated as the dependent variable in the logistic regression analysis, and FGF21, irisin, CRP, gender and BMI were treated as the independent variables, irisin and CRP levels were determined as independent predictors. This study was revealed that there is a negative relationship between sarcopenia and irisin and FGF-21 in operated non-metastatic colorectal cancer patients and there may be a relationship between sarcopenia and inflammation. It suggests that these biomarkers may play a role in the pathophysiology of sarcopenia. However, our results need to be validated in different types of cancer and with more patients.
Identifiants
pubmed: 35277853
doi: 10.1007/s41999-022-00635-3
pii: 10.1007/s41999-022-00635-3
doi:
Substances chimiques
Fibronectins
0
fibroblast growth factor 21
0
Fibroblast Growth Factors
62031-54-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
795-803Informations de copyright
© 2022. The Author(s), under exclusive licence to European Geriatric Medicine Society.
Références
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, European Working Group on Sarcopenia in Older People et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing 39(4):412–423. https://doi.org/10.1093/ageing/afq034
doi: 10.1093/ageing/afq034
pubmed: 20392703
pmcid: 2886201
Cederholm T, Barazzoni R, Austin P et al (2017) ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 36(1):49–64. https://doi.org/10.1016/j.clnu.2016.09.004
doi: 10.1016/j.clnu.2016.09.004
pubmed: 27642056
Chen L-K, Liu L-K, Woo J et al (2014) Sarcopenia in Asia: consensus report of the Asian Working Group for sarcopenia. J Am Med Dir Assoc 15(2):95–101. https://doi.org/10.1016/j.jamda.2013.11.025
doi: 10.1016/j.jamda.2013.11.025
pubmed: 24461239
Kyle UG, Bosaeus I, De Lorenzo AD et al (2004) Bioelectrical impedance analysis—part I: review of principles and methods. Clin Nutr 23(5):1226–1243. https://doi.org/10.1016/j.clnu.2004.06.004
doi: 10.1016/j.clnu.2004.06.004
pubmed: 15380917
Böhm A, Heitmann BL (2013) The use of bioelectrical impedance analysis for body composition in epidemiological studies. Eur J Clin Nutr 67(Suppl 1):S79-85. https://doi.org/10.1038/ejcn.2012.168
doi: 10.1038/ejcn.2012.168
pubmed: 23299875
Marra F, Bertolani C (2009) Adipokines in liver diseases. Hepatology 50:957–969. https://doi.org/10.1002/hep.23046
doi: 10.1002/hep.23046
pubmed: 19585655
Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457–465. https://doi.org/10.1038/nrendo.2012.49
doi: 10.1038/nrendo.2012.49
pubmed: 22473333
Bostrom P, Wu J, Jedrychowski MP et al (2012) A PGC1-alphadependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463–468. https://doi.org/10.1038/nature10777
doi: 10.1038/nature10777
pubmed: 22237023
pmcid: 3522098
Xin C, Liu J, Zhang J et al (2016) Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int J Obes (Lond) 40:443–451. https://doi.org/10.1038/ijo.2015.199
doi: 10.1038/ijo.2015.199
Huh JY, Panagiotou G, Mougios V et al (2012) FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61:1725–1738. https://doi.org/10.1016/j.metabol.2012.09.002
doi: 10.1016/j.metabol.2012.09.002
pubmed: 23018146
pmcid: 3614417
Kurdiova T, Balaz M, Vician M et al (2014) Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol 592:1091–1107. https://doi.org/10.1113/jphysiol.2013.264655
doi: 10.1113/jphysiol.2013.264655
pubmed: 24297848
pmcid: 3948565
Kim HJ, So B, Choi M, Kang D, Song W (2015) Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans. Exp Gerontol 70:11–17. https://doi.org/10.1016/j.exger.2015.07.006
doi: 10.1016/j.exger.2015.07.006
pubmed: 26183690
Pardo M, Crujeiras AB, Amil M et al (2014) Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol 2014:857270. https://doi.org/10.1155/2014/857270
doi: 10.1155/2014/857270
pubmed: 24864142
pmcid: 4016898
Itoh N, Ornitz DM (2011) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149(2):121–130. https://doi.org/10.1093/jb/mvq121
doi: 10.1093/jb/mvq121
pubmed: 20940169
Mashili FL, Austin RL, Deshmukh AS et al (2011) Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev 27(3):286–297. https://doi.org/10.1002/dmrr.1177
doi: 10.1002/dmrr.1177
pubmed: 21309058
Lin Z, Tian H, Lam KSL et al (2013) Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17(5):779–789. https://doi.org/10.1016/j.cmet.2013.04.005
doi: 10.1016/j.cmet.2013.04.005
pubmed: 23663741
Holland WL, Adams AC, Brozinick JT et al (2013) An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 17(5):790–797. https://doi.org/10.1016/j.cmet.2013.03.019
doi: 10.1016/j.cmet.2013.03.019
pubmed: 23663742
pmcid: 3667496
Tuttle CSL, Thang LAN, Maier AB (2020) Share Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis. Ageing Res Rev 64:101185. https://doi.org/10.1016/j.arr.2020.101185
doi: 10.1016/j.arr.2020.101185
pubmed: 32992047
Can B, Kara O, Kizilarslanoglu MC, Arik G, Aycicek GS et al (2017) Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res 29(4):745–752. https://doi.org/10.1007/s40520-016-0626-2
doi: 10.1007/s40520-016-0626-2
pubmed: 27571781
Matsunaga T, Miyata H, Sugimura K, Motoori M, Asukai K et al (2019) Share prognostic significance of sarcopenia and systemic inflammatory response in patients with esophageal cancer. Anticancer Res 39(1):449–458. https://doi.org/10.21873/anticanres.13133
doi: 10.21873/anticanres.13133
pubmed: 30591494
Shokri-Mashhadi N, Moradi S, Heidari Z, Saadat S (2021) Association of circulating C-reactive protein and high-sensitivity C-reactive protein with components of sarcopenia: a systematic review and meta-analysis of observational studies. Exp Gerontol 15(150):111330. https://doi.org/10.1016/j.exger.2021.111330
doi: 10.1016/j.exger.2021.111330
Dupont J, Antonio L, Dedeyne L, O’Neill TW, Vanderschueren D et al (2021) Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years). J Cachexia Sarcopenia Muscle 12(6):1818–1831. https://doi.org/10.1002/jcsm.12785
doi: 10.1002/jcsm.12785
pubmed: 34523822
pmcid: 8718046
Veasey-Rodrigues H, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R (2013) A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle 4(4):259–265. https://doi.org/10.1007/s13539-013-0113-y
doi: 10.1007/s13539-013-0113-y
pubmed: 23893509
pmcid: 3830004
Stene GB, Helbostad JL, Amundsen T, Sorhaug S, Hjelde H, Kaasa S, Grønberg BH (2014) Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol 54(3):340–348. https://doi.org/10.3109/0284186X.2014.953259
doi: 10.3109/0284186X.2014.953259
pubmed: 25225010
Tan BHL, Birdsell LA, Martin L, Baracos VE, Fearon KCH (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15(22):6973–6979. https://doi.org/10.1158/1078-0432.CCR-09-1525
doi: 10.1158/1078-0432.CCR-09-1525
pubmed: 19887488
Daly LE, Ní Bhuachalla ÉB, Power DG, Cushen SJ, James K, Ryan AM (2018) Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle 9(2):315–325. https://doi.org/10.1002/jcsm.12267
doi: 10.1002/jcsm.12267
pubmed: 29318756
pmcid: 5879982
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147:755–763. https://doi.org/10.1093/oxfordjournals.aje.a009520
doi: 10.1093/oxfordjournals.aje.a009520
pubmed: 9554417
Janssen I, Heymsfield SB, Ross R (2002) Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50:889–896. https://doi.org/10.1046/j.1532-5415.2002.50216.x
doi: 10.1046/j.1532-5415.2002.50216.x
pubmed: 12028177
Janssen I, Heymsfield SB, Baumgartner RN et al (2000) Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol 89:465–471. https://doi.org/10.1152/jappl.2000.89.2.465
doi: 10.1152/jappl.2000.89.2.465
pubmed: 10926627
Chien MY, Huang TY, Wu YT (2008) Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. J Am Geriatr Soc 56:1710–1715. https://doi.org/10.1111/j.1532-5415.2008.01854.x
doi: 10.1111/j.1532-5415.2008.01854.x
pubmed: 18691288
Janssen I, Baumgartner R, Ross R et al (2004) Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 159:413–421. https://doi.org/10.1093/aje/kwh058
doi: 10.1093/aje/kwh058
pubmed: 14769646
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T et al (2018) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31. https://doi.org/10.1093/ageing/afz046
doi: 10.1093/ageing/afz046
pmcid: 6322506
Oflazoglu U, Alacacioglu A, Varol U et al (2020) Prevalence and related factors of sarcopenia in newly diagnosed cancer patients. Support Care Cancer 28(2):837–843. https://doi.org/10.1007/s00520-019-04880-4
doi: 10.1007/s00520-019-04880-4
pubmed: 31161438
Hecksteden A, Wegmann M, Steffen A et al (2013) Irisin and exercise training in humans—results from a randomized controlled training trial. BMC Med 11:235. https://doi.org/10.1186/1741-7015-11-235
doi: 10.1186/1741-7015-11-235
pubmed: 24191966
pmcid: 4228275
Huh JY, Mougios V, Kabasakalis A et al (2014) Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab 99:2154–2161. https://doi.org/10.1210/jc.2014-1437
doi: 10.1210/jc.2014-1437
Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF (2013) Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—correlation with body mass index. Peptides 39:125–130. https://doi.org/10.1016/j.peptides.2012.11.014
doi: 10.1016/j.peptides.2012.11.014
pubmed: 23219488
Chang JS, Kim TH, Nguyen TT, Park K-S, Kim N, Kong ID (2017) Circulating irisin levels as a predictive biomarker for sarcopenia: a cross-sectional community-based study. Geriatr Gerontol Int 17:2266–2273. https://doi.org/10.1111/ggi.13030
doi: 10.1111/ggi.13030
pubmed: 28394089
Choi HY, Kim S, Park JW, Lee NS, Hwang SY et al (2014) Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans. J Clin Endocrinol Metab 99(8):2778–2785. https://doi.org/10.1210/jc.2014-1195
doi: 10.1210/jc.2014-1195
pubmed: 24780049
Tezze C, Romanello V, Desbats MA, Fadini GP, Albiero M, Favaro G et al (2017) Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence. Cell Metab 25:1374-1389.e6. https://doi.org/10.1016/j.cmet.2017.04.021
doi: 10.1016/j.cmet.2017.04.021
pubmed: 28552492
pmcid: 5462533
Hanks LJ, Gutierrez OM, Bamman MM, Ashraf A, McCormick KL, Casazza K et al (2015) Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J Clin Transl Endocrinol 2:77–82. https://doi.org/10.1016/j.jcte.2015.02.001
doi: 10.1016/j.jcte.2015.02.001
pubmed: 26042208
pmcid: 4450097
Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Åkerstrom T, Nielsen S, Pedersen BK (2009) Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 58(12):2797–2801. https://doi.org/10.2337/db09-0713
doi: 10.2337/db09-0713
pubmed: 19720803
pmcid: 2780875
Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246–1253. https://doi.org/10.2337/db07-1476
doi: 10.2337/db07-1476
pubmed: 18252893
Keipert S, Ost M, Johann K, Imber F, Jastroch M, van Schothorst EM (2014) Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine. Am J Physiol Endocrinol Metab 306:469–482. https://doi.org/10.1152/ajpendo.00330.2013
doi: 10.1152/ajpendo.00330.2013
Srdic D, Plestina S, Sverko-Peternac A, Nikolac N, Simundic A-M et al (2016) Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer 24(11):4495–4502. https://doi.org/10.1007/s00520-016-3287-y
doi: 10.1007/s00520-016-3287-y
pubmed: 27236439
Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, Harris TB (2002) Relationship of interleukin-6 and tumour necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the health ABC study. J Gerontol A Biol Sci Med Sci 57:M326–M332. https://doi.org/10.1093/gerona/57.5.m326
doi: 10.1093/gerona/57.5.m326
pubmed: 11983728
Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BW, Lenchik L, Palla SL, Ambrosius WT, Tracy RP, Pahor M (2005) Sarcopenia, obesity, and inflammation: results from the trial of angiotensin converting enzyme inhibition and novel cardiovascular risk factors study. Am J Clin Nutr 82:428–434. https://doi.org/10.1093/ajcn.82.2.428
doi: 10.1093/ajcn.82.2.428
pubmed: 16087989
Ferrucci L, Penninx BW, Volpato S, Harris TB, Bandeen-Roche K et al (2002) Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc 50:1947–1954. https://doi.org/10.1046/j.1532-5415.2002.50605.x
doi: 10.1046/j.1532-5415.2002.50605.x
pubmed: 12473005
Oflazoglu U, Alacacioglu A, Varol U et al (2020) The role of inflammation in adjuvant chemotherapy-induced sarcopenia (Izmir Oncology Group (IZOG) study). Support Care Cancer 28(8):3965–3977. https://doi.org/10.1007/s00520-020-05477-y
doi: 10.1007/s00520-020-05477-y
pubmed: 32335732
Oflazoglu U, Alacacioglu A, Varol U et al (2020) Chemotherapy-induced sarcopenia in newly diagnosed cancer patients: Izmir Oncology Group (IZOG) study. Support Care Cancer 28(6):2899–2910. https://doi.org/10.1007/s00520-019-05165-6
doi: 10.1007/s00520-019-05165-6
pubmed: 31758325
Pamoukdjian F, Bouillet T, Lévy V, SoussanM ZL, Paillaud E (2018) Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clin Nutr 37(4):1101–1113. https://doi.org/10.1016/j.clnu.2017.07.010
doi: 10.1016/j.clnu.2017.07.010
pubmed: 28734552
Williams JR, Deal GR, Yu AM et al (2015) Prevalence of sarcopenia in older patients with colorectal cancer. J Geriatr Oncol 6(6):442–445. https://doi.org/10.1016/j.jgo.2015.08.005
doi: 10.1016/j.jgo.2015.08.005
pubmed: 26365898
pmcid: 7108316